ENLIVEX THERAPEUTICS LTD (ENLV)

IL0011319527 - Common Stock

1.46  -0.02 (-1.28%)

Fundamental Rating

2

Taking everything into account, ENLV scores 2 out of 10 in our fundamental rating. ENLV was compared to 582 industry peers in the Biotechnology industry. While ENLV seems to be doing ok healthwise, there are quite some concerns on its profitability. ENLV is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

ENLV had negative earnings in the past year.
ENLV had a negative operating cash flow in the past year.
ENLV had negative earnings in each of the past 5 years.
In the past 5 years ENLV always reported negative operating cash flow.

1.2 Ratios

ENLV has a worse Return On Assets (-78.93%) than 71.06% of its industry peers.
ENLV has a Return On Equity (-96.63%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -78.93%
ROE -96.63%
ROIC N/A
ROA(3y)-46.68%
ROA(5y)-44.78%
ROE(3y)-56.09%
ROE(5y)-57.3%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ENLV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ENLV has more shares outstanding
ENLV has more shares outstanding than it did 5 years ago.
ENLV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ENLV has an Altman-Z score of -2.89. This is a bad value and indicates that ENLV is not financially healthy and even has some risk of bankruptcy.
ENLV has a Altman-Z score (-2.89) which is comparable to the rest of the industry.
There is no outstanding debt for ENLV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.89
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ENLV has a Current Ratio of 5.57. This indicates that ENLV is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.57, ENLV perfoms like the industry average, outperforming 56.85% of the companies in the same industry.
A Quick Ratio of 5.57 indicates that ENLV has no problem at all paying its short term obligations.
ENLV's Quick ratio of 5.57 is in line compared to the rest of the industry. ENLV outperforms 57.37% of its industry peers.
Industry RankSector Rank
Current Ratio 5.57
Quick Ratio 5.57

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.69% over the past year.
EPS 1Y (TTM)7.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ENLV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.08% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.77%
EPS Next 2Y28.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENLV. In the last year negative earnings were reported.
Also next year ENLV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ENLV's earnings are expected to grow with 28.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.08%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ENLV!.
Industry RankSector Rank
Dividend Yield N/A

ENLIVEX THERAPEUTICS LTD

NASDAQ:ENLV (6/14/2024, 7:05:41 PM)

1.46

-0.02 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap30.16M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.93%
ROE -96.63%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.57
Quick Ratio 5.57
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)7.69%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y43.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y